On Jun. 24, 2020, Oncotelic, a wholly owned subsidiary of Mateon Therapeutics, announced that IBM has granted access to its IBM Clinical Development (ICD) platform free of charge for the clinical trial evaluating the potential of Mateonﾒs lead drug candidate OT-101 in COVID-19 patients.

The award was made following IBMﾒs review of the program and is designed to help accelerate the upcoming phase II COVID-19 clinical trial. IBM is supporting COVID-19 clinical research through an initiative to help support trial sponsors with promising therapeutic and vaccine candidates.